+223.7%
MNST vs MRNA
+915.3%
-691.6%
-27.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +2.0% | -3.4% | +5.4% | +2.0% |
| 7D | +1.6% | -12.1% | +13.7% | +1.9% |
| 30D | +5.1% | -1.3% | +6.4% | +5.0% |
| 3M | -0.5% | +250.9% | -251.4% | -6.0% |
| 6M | +8.1% | +343.0% | -334.9% | +0.6% |
| YTD | +21.2% | +657.4% | -636.2% | +9.6% |
| 1Y | +30.7% | +794.9% | -764.2% | +17.2% |
| 3Y | +67.3% | +218.1% | -150.8% | +54.1% |
| 5Y | +101.9% | -3.4% | +105.3% | +92.5% |
| All | +223.7% | +915.3% | -691.6% | +164.1% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling